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Abstract
Functional links between bone remodeling and the immune
system in chronic inflammatory arthritis are mediated, in part, by
the ligand of receptor activator of nuclear factor-kappa-B
(RANK-L). Because neutrophils play a crucial role in chronic
inflammation, the goal of this study was to determine whether
proteins of the RANK/RANK-L pathway are expressed by
synovial fluid (SF) neutrophils from patients with rheumatoid
arthritis (RA) and to characterize this pathway in normal human
blood neutrophils. The expression of RANK-L, osteoprotegerin
(OPG), RANK, and tumor necrosis factor receptor-associated
factor 6 (TRAF6) was determined by polymerase chain reaction,
enzyme-linked immunosorbent assay, Western blotting, and
cytofluorometry. RANK signaling was analyzed by the
degradation of inhibitor of kappaB-alpha (I-κB-α). SF
neutrophils from patients with RA express and release OPG and
express the membrane-associated forms of RANK-L and RANK.
In contrast, normal blood neutrophils express only the
membrane-associated form of RANK-L. They do not express the
mRNAs encoding OPG and RANK. SF neutrophils from RA
patients and normal blood neutrophils release no soluble RANK-
L. They express the mRNA for TRAF6. The expression of OPG
and RANK by normal human blood neutrophils, however, can be
induced by interleukin-4 + tumor necrosis factor-alpha and by
SFs from patients with RA. In contrast, SFs from patients with
osteoarthritis do not induce the expression of OPG and RANK.
Moreover, the addition of RANK-L to normal blood neutrophils
pretreated by SF from patients with RA decreased I-κB-α,
indicating that RANK signaling by neutrophils stimulated with SF
is associated with nuclear factor-kappa-B activation. In
summary, RANK-L is expressed by inflammatory and normal
neutrophils, unlike OPG and RANK, which are expressed only
by neutrophils exposed to an inflammatory environment. Taken
together, these results suggest that neutrophils may contribute
to bone remodeling at inflammatory sites where they are present
in significantly large numbers.
Introduction
Neutrophils, which are among the first cells to arrive in
inflamed tissues, are activated during their margination and
diapedesis across blood vessels and by cytokines at the site
of inflammation [1]. They are involved in various chronic inflam-
matory diseases such as arthritis, active autoimmune colitis,
and skin lesions of psoriasis [2,3]. In rheumatoid arthritis (RA),
neutrophils are found in synovial fluids (SFs) and at the rheu-
matoid pannus-cartilage junction. They can degrade cartilage
constituents [4,5]. The essential role of neutrophils in the
initiation and maintenance of inflammation in the affected
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joints in RA was confirmed by the K/BxN mouse model of RA
[6].
Besides their role in innate immunity, neutrophils act as anti-
gen-presenting cells and regulate the adaptive immune
response [7]. In the presence of certain cytokines, neutrophils
acquire a variety of biological characteristics – such as the
expression of major histocompatibility complex (MHC) class II
antigens – that enable them to function as antigen-presenting
cells [8,9]. In addition, phlogogenic cytokines activate neu-
trophils to express CCR6, CD80, CD83, CD86, and CD40,
an expression pattern that resembles a dendritic-like pheno-
type [10,11]. The in vitro observation that neutrophils differen-
tiate into dendritic-like cells has been corroborated in vivo by
the demonstration that they express MHC class II, CD80, and
CD86 proteins and that they can present antigens to T cells in
an MHC class II-restricted manner in Wegener granulomatosis
and RA [12,13]. The same inflammatory conditions that induce
neutrophils to differentiate into dendritic-like cells have the
capacity to delay the apoptosis of neutrophils, which are cells
that are constitutively programmed for apoptotic cell death
[14].
During the immune response, mature dendritic cells express
receptor activator of nuclear factor-kappa-B (RANK) and
tumor necrosis factor receptor-associated factor 6 (TRAF6)
[15,16]. TRAF6 is an adapter protein implicated in signaling
pathways of immunity and bone homeostasis [16]. RANK is
activated by tumor necrosis factor-related activation-induced
cytokine (TRANCE) [15]. TRANCE is a new member of the
tumor necrosis factor (TNF) family and prevents apoptosis,
increases survival, and stimulates cytokine production in den-
dritic cells [17,18]. TRANCE and the ligand of RANK (RANK-
L) were originally cloned and sequenced from T lymphocytes
[15,17]. They are also known as osteoprotegerin (OPG) lig-
and and osteoclast differentiation factor based on their capac-
ity to induce osteoclastogenesis and activate osteoclasts via
RANK [19-21]. Bone resorption is dependent upon osteob-
last-osteoclast interactions that are mediated through the
osteoblastic expression of a membrane form of RANK-L. This
protein can also be processed into a soluble and active extra-
cellular form [22]. In the presence of certain stimuli, cells can
express both RANK-L and RANK, an observation reported in T
lymphocytes [15,23]. These studies have shed light on the
molecular and functional links between bone remodeling and
the immune system. T lymphocytes, for instance, promote
bone loss in inflammatory arthritis by expressing RANK-L that
directly binds and activates osteoclasts [24].
The observation that neutrophils can differentiate into den-
dritic-like cells led us to test the hypothesis that inflammatory
neutrophils could express proteins common to the local
immune response and bone remodeling, such as those of the
RANK/RANK-L pathway. To address this question, we investi-
gated the expression of RANK-L, OPG, RANK, and TRAF6
mRNAs and proteins in neutrophils from the SF of patients
with RA. Human blood neutrophils from healthy subjects were
studied as normal control cells. Moreover, we demonstrate
that the expression of genes of the RANK/RANK-L pathway
could be induced by certain stimuli in neutrophils in vitro. The
effect of SFs from patients with RA and from patients with
osteoarthritis (OA) on the expression of these genes by normal
neutrophils was also evaluated. Our observations suggest that
the proteins of the RANK/RANK-L pathway expressed by neu-
trophils mediate important functions of neutrophils during the
abnormal immune response and bone remodeling in RA.
Materials and methods
Reagents
Ficoll-Paque (1.077 density), RPMI 1640, Hanks' balanced
salt solution (HBSS), and fetal bovine serum (FBS) were pur-
chased from WISENT Inc. (St-Bruno, QC, Canada). Terminal
deoxynucleotidyl transferase was purchased from Amersham
Biosciences Inc. (now part of GE Healthcare, Little Chalfont,
Buckinghamshire, UK). Trizol reagents and the Superscript™ II
Reverse Transcriptase (RT) kit were obtained from Invitrogen
Corporation (Carlsbad, CA, USA). Oligo-dT primers and Taq
DNA polymerase were purchased from PerkinElmer Life and
Analytical Sciences (Woodbridge, ON, Canada). The goat
polyclonal anti-human RANK-L immunoglobulin (Ig) G anti-
body (Ab) (sc-7627) was purchased from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA, USA). The mouse monoclonal
anti-human RANK Ab was obtained from Alexis Biochemicals
(part of Axxora Life Sciences, Inc., San Diego, CA, USA). The
rabbit polyclonal anti-human inhibitor of kappaB-alpha Ab (no.
9242) was purchased from Cell Signaling Technology, Inc.
(Danvers, MA, USA). Human recombinant RANK-L was
obtained from PeproTech (Rocky Hill, NJ, USA). The human
RANK cDNA was a kind gift from Dr. Naoki Sakurai (Discovery
Research Laboratory, Tanabe Seiyaku Co., Ltd., Yodogawa-
ku, Osaka, Japan).
Cell preparation and culture conditions
The institutional review board of the Université Laval (Québec,
QC, Canada) approved the present study, and volunteers
signed a consent form. Samples were collected in anticoagu-
lant solution, and cells were isolated under sterile conditions.
Cells were obtained from the human venous blood of healthy
donors and from the SF of seven patients with RA (according
to the revised criteria of the American College of Rheumatol-
ogy). Characteristics of patients with RA were as follows: six
women/one man, age at onset of symptoms 52.1 ± 16.2 years
(mean ± standard deviation [SD]), time between onset of
symptoms and the present study 4.6 ± 4.0 years (mean ± SD),
clinical parameters at the present examination: erythrocyte
sedimentation rate (ESR) 27.6 ± 15.6 mm (mean ± SD), and
C-reactive protein 36.2 ± 31.7 g/l (mean ± SD). Four patients
were positive for IgM-rheumatoid factor (RF), and three were
negative for IgM-RF. Four patients had radiographic erosions,
two had local osteoporosis of inflammatory joints, and oneAvailable online http://arthritis-research.com/content/9/2/R25
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showed no radiographic symptoms. Three patients had under-
gone no treatment, one was taking non-steroidal anti-inflam-
matory drugs, one was taking 5 mg/day prednisone, and two
were taking disease-modifying anti-rheumatic drugs. Due to
limited quantities of SF and neutrophils from patients with RA
and due to the requirement of large numbers of cells depend-
ing on the experiments performed (described below), it was
not possible to systematically include the cells of the seven
patients in all the experiments reported.
Blood was centrifuged (250 g, 15 minutes) and the platelet-
rich plasma was removed. The peripheral blood polymorpho
(neutrophils) and mononuclear leukocyte (PBML) fractions
were obtained by centrifugation over Ficoll-Paque after dex-
tran sedimentation [25]. Remaining erythrocytes were elimi-
nated by hypotonic lysis. SF neutrophils were directly obtained
by centrifugation over Ficoll-Paque. After two washes, cells
were counted and resuspended in culture medium. Differential
cell counts of leukocytes were performed by cytofluorometry
(EPICS-XL; Beckman Coulter, Fullerton, CA, USA) and
Wright's and non-specific esterase stains. Neutrophil suspen-
sions were more than 98% pure with no CD3-positive cells,
and non-specific esterase-positive cells represented less than
0.2% of the cell population.
Cells were incubated in 12-well plates (2 ml/well) at 37°C and
5% CO2 for up to 4 days. Two culture media were studied. The
control medium (CM) was RPMI 1640 and 10% FBS, and the
survival medium (SM) consisted of CM supplemented with
500 pM granulocyte-macrophage colony-stimulating factor
(GM-CSF), 10 ng/ml interleukin (IL)-4, and 10 ng/ml TNF-α.
The cytokines present in SM were chosen for their anti-apop-
totic effects on neutrophils [10,26,27]. Cells and supernatants
were collected from days 1 to 4. After centrifugation (5,000 g,
2 minutes), cell pellets were resuspended in 1 ml of Trizol for
RNA isolation or sonicated in 0.5 ml of HBSS (no. 211–512)
for enzyme immunometric assay (EIA) analysis of cell-associ-
ated materials. These samples were frozen at -20°C until
assayed. When required, samples of neutrophil supernatants
were concentrated by centrifugation over Amicon Ultra 10000
MW CO (Millipore Corporation, Billerica, MA, USA) at 5,000
g for 1 hour at 4°C. Normal peripheral blood neutrophils (107/
ml) were also incubated at 37°C and 5% CO2 for 3 days in the
presence of acellular SF from four of the seven RA patients
described above and in the presence of acellular SF from two
patients with OA. The incubation media consisted of 80% SF
and 20% CM.
Analysis by reverse transcriptase-polymerase chain 
reaction
Total RNA was isolated from cells by means of the Trizol rea-
gent, and RT reaction was performed with Superscript™ II RT
according to the manufacturer's instructions. The cDNAs were
amplified by polymerase chain reaction (PCR) using gene-
specific primer pairs designed with Primer 3 software (White-
head Institute for Biomedical Research, Cambridge, MA, USA)
(Table 1). Each PCR was performed with one tenth of the vol-
ume of cDNA from the RT reaction, 10 μM forward and
reverse primers, 200 μM dNTPs, 2.5 μl 10× PCR buffer (200
mM Tris-HCl pH 8.4, 500 mM KCl), 1 to 1.5 mM MgCl2, 0.5 U
Taq DNA polymerase, and autoclaved, distilled water to obtain
a final volume of 25 μl. The number of cycles corresponding to
the linear phase of amplification and the annealing tempera-
ture were optimized for each primer set (Table 1). The human
β-actin transcript was used to standardize between PCRs.
The PCR products were separated on a 1% agarose gel by
electrophoresis in Tris acetic acid EDTA (ethylenediamine-
tetraacetic acid) buffer and visualized using ethidium bromide.
The sequence of the amplified gene fragments was deter-
mined by direct sequencing.
EIA analysis of RANK-L and OPG
The EIAs used were at two sites with horseradish peroxidase
(HRP) as a tracer. Ninety-six-well plates were coated with
either the human OPG/Fc Chimera (805-OS; R&D Systems,
Inc., Minneapolis, MN, USA) or a monoclonal anti-human OPG
Ab (MAB8051; R&D Systems, Inc.) in phosphate-buffered
solution (pH 7.4). A biotinylated secondary goat anti-human
RANK-L Ab (BAF626; R&D Systems, Inc.) or a compatible
biotinylated secondary goat anti-human OPG Ab (BAF805;
R&D Systems, Inc.) in phosphate-buffered solution (pH 7.4)
containing bovine serum albumin (BSA) was used. Antigen-Ab
complexes were detected by the addition of a streptavidin-
HRP conjugate and tetramethylbenzidine as a substrate for
HRP. Concentrations of RANK-L and OPG were obtained
from a standard curve generated by known concentrations of
human RANK-L and OPG. The detection limits were 15 and
7.5 pg/ml for RANK-L and OPG, respectively.
Western blot analysis
SF neutrophils (3 × 106) from four patients with RA were sol-
ubilized in SDS sample buffer. The positive control was COS-
7 cells transiently transfected (Fugene 6 transfection reagent;
Roche Diagnostics, Indianapolis, IN, USA) with human RANK
cDNA. Transfected cells were lysed in 1.5% Triton X-100 at
4°C for 5 minutes, and samples were analyzed on a 7% SDS-
polyacrylamide gel. The proteins were transferred to a polyvi-
nylidene difluoride (PVDF) membrane (Millipore Corporation)
at 4°C overnight. The membrane was blocked with 2% pig gel-
atin in tris-buffered saline (TBS) with 6% Tween 20 for 60 min-
utes, incubated with 0.2 μg/ml of a goat anti-human RANK IgG
Ab (no. AF683; R&D Systems, Inc.), washed three times in
TBS-Tween, and incubated with 0.04 μg/ml of a rabbit HRP-
conjugated anti-goat IgG Ab (The Jackson Laboratory, Bar
Harbor, ME, USA). After incubation in SF from patients with
RA for 3 days (see above), healthy blood neutrophils were
centrifuged at 600 g for 30 minutes on a percoll gradient to
remove debris and dead cells [28], washed, resuspended in
HBSS (15 × 106 cells per milliliter), and stimulated at 37°C by
50 ng/ml TNF-α for 10 minutes or by 100 ng/ml RANK-L forArthritis Research & Therapy    Vol 9 No 2    Poubelle et al.
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10 and 20 minutes. They were then transferred to 2× boiling
Laemmli's sample buffer (1×: 62.5 mM Tris/HCl [pH6.8], 4%
[wt/vol] SDS, 5% [vol/vol] 2-mercaptoethanol, 8.5% [vol/vol]
glycerol, 2.5 mM orthovanadate, 10 mM para-nitrophenylphos-
phate, 10 μg/ml leupeptin, 10 μg/ml aprotinin, and 0.025%
bromophenol blue). Proteins were separated on a 12% SDS-
PAGE gel and transferred on a PVDF membrane. Immunoblot-
ting was performed using 5% Blotto as a blocking agent. The
primary Ab directed against I-κB-α was diluted 1:1,000 in
TBS-Tween 5% BSA and incubated with the membrane for 1
hour. The goat HRP-conjugated anti-rabbit IgG Ab (The Jack-
son Laboratory) was diluted 1:20,000 and incubated with the
membrane. The labeled Abs were detected by the ECL
(enhanced chemiluminescence) detection system (GE Health-
care) and visualized on Kodak Biomax MR film (Eastman
Kodak, Rochester, NY, USA).
Cytofluorometry
The expression of RANK-L and RANK at the membrane was
evaluated by cytofluorometry. Freshly separated healthy
human blood or SF neutrophils from patients with RA and
healthy neutrophils incubated in SFs were incubated with a
goat anti-human RANK-L Ab (Santa Cruz Biotechnology, Inc.)
followed by a fluorescein isothiocyanate (FITC)-conjugated
anti-goat F(ab')2 Ab. A normal goat IgG was used as control.
To evaluate cell surface expression of RANK, healthy human
blood neutrophils incubated in SFs were fixed and
permeabilized using the Fixation/Permeabilization Solution kit
(no. 554723) from BD Biosciences Pharmingen (San Diego,
CA, USA). Briefly, non-specific staining of Fc receptors was
blocked by 10% human decomplemented serum before cells
were resuspended in 250 μl of Fixation/Permeabilization Solu-
tion (BD Cytofix/Cytoperm no. 554714) for 45 minutes at 4°C.
Cells were then washed and permeabilized with BD Perm/
Wash buffer in the presence of 10% mouse non-specific
immune serum. Fixed and permeabilized neutrophils were then
stained with a mouse monoclonal anti-human RANK Ab (ALX-
804-212-C100) followed by a FITC-conjugated anti-mouse
F(ab')2  Ab. Corresponding controls with non-specific Abs
were also performed.
Viability
Neutrophil viability was evaluated by the lactate dehydroge-
nase (LDH) release assay. Neutrophil suspensions after incu-
bation were centrifuged (5,000 g, 1 minute). Supernatants
and pelleted neutrophils were collected separately, and cells
were lysed in 1% Triton X-100 buffer. Prior to colorimetric
analysis at 340 nm, 1.25 ml of substrate (0.14 mg/ml NADH
in 0.1 M sodium phosphate buffer, pH 7.35) and 50 μl of pyru-
vate solution were added to 50 μl of cell lysate or supernatant.
Results were expressed as percentages of the ratio between
the optical density values measured in supernatants and the
total optical density value measured in cells plus supernatants.
Viable neutrophils that did not release LDH at day 3 repre-
sented 32% and 39% in CM and SM, respectively.
Statistics
Values were expressed as means ± standard error of the mean
(SEM) of n experiments performed with cells from different
donors. Statistical analyses were performed using GraphPad
Instat 3.0 (GraphPad Software, Inc., San Diego, CA, USA).
Non-parametric analysis with the Mann-Whitney test was used
to compare the means of two groups. Paired groups were ana-
Table 1
DNA sequences of the forward and reverse primers for the qualitative and semi-quantitative reverse transcriptase-polymerase 
chain reaction analyses
Gene identity Accession 
number
Primer sequencesa Annealing 
temperature (°C)
Number of cycles 
(Quan.)b
Number of cycles 
(Qual.)c
Size of PCR product 
(bp)
RANK-L AF019047 5'-CTG-ATG-AAA-GGA-GGA-AGC-AC-3' 65 29 35 546
5'-GAT-GAC-ACC-CTC-TCC-ACT-TC-3'
OPG U94332 5'-TGC-TGT-TCC-TAC-AAA-GTT-TAC-G-3' 56 35 40 433
5'-CTT-TGA-GTG-CTT-TAG-TGC-GTG-3'
RANK AF018253 5'-CCT-GGA-CCA-ACT-GTA-CCT-TC-3' 58 34 40 500
5'-TTC-CTC-TAT-CTC-GGT-CTT-GC-3'




58 21 28 375
5'-CTC-AGG-AGG-AGC-AAT-GAT-CTT-
GAT-3'
aFor each pair of sequences, the forward primer appears first and the reverse primer appears second. bThe number of cycles used in the semi-
quantitative (quan.) PCR experiments corresponds to the linear phase of the amplification reaction. cThe number of cycles used in the qualitative 
(qual.) PCR experiments was increased to allow the possible detection of the mRNA. OPG, osteoprotegerin; PCR, polymerase chain reaction; 
RANK, receptor activator of nuclear factor-kappa-B; RANK-L, ligand of receptor activator of nuclear factor-kappa-B; TRAF6, tumor necrosis factor 
receptor-associated factor 6.Available online http://arthritis-research.com/content/9/2/R25
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lyzed using the paired t test. Significance was set at a two-
tailed p value of less than 0.05.
Results
Expression of RANK-L, OPG, RANK, and TRAF6 mRNAs 
by SF neutrophils from patients with RA and by healthy 
human blood cells
Freshly isolated neutrophils from SF of patients with RA
expressed RANKL, OPG, TRAF6, and RANK as determined
by semi-quantitative RT-PCR (Figure 1a). In contrast, freshly
isolated peripheral blood neutrophils from healthy subjects
expressed RANK-L and TRAF6, but not OPG and RANK (Fig-
ure 1a). PBMLs from healthy subjects expressed the four
genes tested, and platelets expressed RANK-L, TRAF6, OPG,
and not RANK (Figure 1b). The absence of OPG or RANK
expression in healthy neutrophils was confirmed by qualitative
PCR using an increasing number of cycles as indicated in
Table 1 (data not shown). The fact that PBMLs expressed
OPG and RANK mRNA enabled us to confirm that the neu-
trophil and platelet preparations were not contaminated by
these cells.
Expression of RANK-L, OPG, and RANK proteins by SF 
neutrophils from patients with RA
Freshly isolated neutrophils from SF of patients with RA
expressed not only the mRNA of the four genes studied (Fig-
ure 1a) but also the corresponding proteins RANK-L, OPG,
and RANK (Figure 2). Cell-associated materials of SF neu-
trophils from patients with RA contained detectable amounts
of RANK-L and OPG as measured by EIAs (Figure 2a,c). In
contrast, cell-associated materials of healthy blood neutrophils
contained 68 ± 13 pg/ml RANK-L and no OPG (n = 13). SF
neutrophils obtained from patients with RA and incubated for
up to 4 days in CM (as described in Materials and methods
and Figure 2a) or in SM (data not shown) did not release
Figure 1
Expression of RANK-L, OPG, RANK, and TRAF6 mRNAs by synovial fluid (SF) neutrophils isolated from patients with rheumatoid arthritis (RA) and  by normal blood cells Expression of RANK-L, OPG, RANK, and TRAF6 mRNAs by synovial fluid (SF) neutrophils isolated from patients with rheumatoid arthritis (RA) and 
by normal blood cells. (a) Purified neutrophils of SF from four patients with RA and of blood from seven normal donors were evaluated by semi-quan-
titative reverse transcriptase-polymerase chain reaction (RT-PCR) analyses. (b) Purified peripheral blood mononuclear leukocytes (PBMLs) and 
platelets of blood from seven normal donors were evaluated by semi-quantitative RT-PCR analyses. To avoid leukocyte contamination in the platelet 
suspension, platelets were isolated from the upper part of the platelet-rich plasma (PRP). After centrifugation (600 g, 30 minutes), the pellets were 
resuspended in Trizol. No contaminating leukocytes in the upper part of the PRP were observed under light microscopy after Wright's stain. Histo-
grams represent mean ± standard error of the mean of ratios of densitometric values for RANK-L/β-actin, OPG/β-actin, RANK/β-actin, and TRAF6/
β-actin. OPG, osteoprotegerin; RANK, receptor activator of nuclear factor-kappa-B; RANK-L, ligand of receptor activator of nuclear factor-kappa-B; 
TRAF6, tumor necrosis factor receptor-associated factor 6.Arthritis Research & Therapy    Vol 9 No 2    Poubelle et al.
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RANK-L. However, freshly isolated SF neutrophils of patients
with RA, as well as healthy blood neutrophils, expressed
RANK-L protein on their plasma membrane, as evaluated by
cytofluorometry (Figure 2b). Percentages of RANK-L-positive
neutrophils freshly isolated from SF of patients with RA (n = 5)
and from normal blood (n = 13) were 10.9% ± 4.3% and 2.9%
± 0.7%, respectively (p = 0.09). Moreover, the same SF neu-
trophils obtained from patients with RA and incubated for up
to 4 days in CM showed a time-dependent release and accu-
mulation of OPG in supernatants (Figure 2c). Finally, the
expression of RANK protein was also determined by Western
blot analysis in freshly isolated SF neutrophils of four patients
with RA. The SF neutrophils of two of the four patients studied
expressed a detectable band of an apparent molecular weight
of 110 kDa. This band is specific for the polyclonal anti-human
RANK Ab as shown in COS cells transiently transfected with
a human RANK cDNA (Figure 2d). The amounts of OPG and
RANK-L in SFs of the same patients with RA were also quan-
titated by EIA. SFs of patients with RA contained 6,990 ±
1,912 pg/ml OPG and 21 ± 12 pg/ml RANK-L (mean ± SEM,
n = 7) with a RANK-L/OPG ratio of 0.003.
Normal human blood neutrophils can acquire the 
capacity to express OPG and RANK
We next investigated whether in vitro conditions could mimic
our in vivo observations (Figures 1 and 2). Neutrophils were
incubated with cytokines that decrease neutrophil apoptosis
and that are found in SFs from patients with RA [29]. Healthy
blood neutrophils were shown to express RANK-L  mRNA
under CM and SM conditions without any significant changes
from day 1 to day 3 (Figure 3). The expression of OPG mRNA
by neutrophils incubated in CM was not yet detectable on day
2 and appeared only after 3 days (Figure 3). The incubation of
neutrophils in SM, however, strikingly upregulated the expres-
sion of this gene. The expression of OPG mRNA, which was
absent at day 0 (Figure 1a), significantly increased at days 1,
2, and 3 (Figure 3). Control studies using different combina-
tions of the cytokines were also conducted. Neutrophils incu-
bated for 3 days in medium containing TNF-α alone expressed
RANK-L but not OPG. When IL-4 was present, alone or in
combination with GM-CSF or TNF-α, neutrophils expressed
OPG with no change of RANK-L. GM-CSF alone had no effect
on the expression of the genes tested (data not shown).
Healthy blood neutrophils that do not express RANK at day 0
(Figure 1a) have the capacity to express RANK mRNA in vitro
when incubated in SM (Figure 3). The expression of RANK by
neutrophils was detectable from day 2 to day 3 (results
observed in two donors out of nine healthy subjects studied).
The expression of TRAF6 by normal blood neutrophils, on the
other hand, was detected in all the conditions tested but
decreased significantly at day 3 in the presence of SM (Figure
3). In contrast, PBMLs expressed OPG and RANK from day 0
(Figure 1b) to day 3 (data not shown). In these cells, a
decrease in the expression of OPG and RANK was observed
when incubated in CM and an increase was observed when
incubated in SM. TRAF6 expression by PBMLs was similar in
CM and in SM with no significant changes from days 1 to 3
(data not shown).
These findings were then confirmed at the protein level. Incu-
bation of healthy blood neutrophils in CM or SM conditions for
up to 3 days did not modify the membrane expression of
RANK-L as evaluated by cytofluorometry and did not stimulate
the release of detectable amounts of OPG in neutrophil super-
natants as measured by EIA (data not shown). Prolongation of
the incubation time up to 5 days in SM, however, led to an
accumulation of OPG in the supernatants of these neutrophils
(2.0 ± 0.4 pg/ml, n = 7). Moreover, the same neutrophil super-
natants contained no RANK-L as evaluated by EIA (data not
shown). In contrast, PBMLs cultured under similar conditions
secreted RANK-L and OPG in the supernatants (data not
shown), confirming that neutrophils and PBMLs expressed
RANK-L and OPG differently.
SF from patients with RA activates the expression of 
RANK-L, OPG, and RANK in normal blood neutrophils
Having established that inflammatory cytokines can stimulate
healthy blood neutrophils to express OPG and RANK (Figure
3) and that SF neutrophils from patients with RA
spontaneously expressed RANK-L, OPG, and RANK proteins
(Figure 2), we next investigated the effect of SF on the expres-
sion of these genes by incubating healthy human blood neu-
trophils in the presence of SF from patients with RA (Figure 4).
After 2 days of incubation of healthy blood neutrophils in
medium containing 80% SF from patients with RA and 20%
CM, membrane RANK-L significantly increased and was
detected on 13.4% ± 4.7% of cells (n = 5) (versus 2.5% ±
0.8% neutrophils in CM alone, a percentage similar to that of
freshly isolated neutrophils). Similar experiments with incuba-
tion medium containing SF from patients with OA revealed
that 3.9% ± 0.5% of neutrophils expressed membrane RANK-
L (n = 14) (Figure 4a). The difference in the expression of
membrane RANK-L in healthy blood neutrophils incubated in
SF from patients with RA versus patients with OA was signifi-
cant (p = 0.019). Moreover, SF from patients with RA, but not
patients with OA, activated healthy blood neutrophils to
express OPG and RANK mRNAs as evaluated by RT-PCR
(Figure 4b). Finally, SFs from patients with RA, but not from
patients with OA, strongly activated healthy blood neutrophils
to express RANK at the cell surface. Membrane RANK, which
is not expressed by freshly isolated human blood neutrophils
(data not shown), was detected on 15.3% ± 5.6% of cells
after 3 days of incubation in the presence of SF of patients
with RA (Figure 4c).
The release of active nuclear factor-kappa-B (NF-κB) second-
ary to the stimulation of RANK by RANK-L is associated with
the phosphorylation of the inhibitory I-κB-α protein. Subse-
quently, I-κB-α decreased through its conjugation with ubiqui-
tin and its degradation by proteasome. To determine whetherAvailable online http://arthritis-research.com/content/9/2/R25
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Figure 2
Expression of RANK-L, OPG, and RANK proteins by synovial fluid (SF) neutrophils from patients with rheumatoid arthritis (RA) Expression of RANK-L, OPG, and RANK proteins by synovial fluid (SF) neutrophils from patients with rheumatoid arthritis (RA). (a) Cell-associated 
materials and supernatants of SF neutrophils (107/ml) from three patients with RA were analyzed by enzyme immunometric assays (EIAs) for RANK-
L at day 0 and after 2 and 4 days of incubation in control medium. (b) Surface expression of RANK-L by freshly isolated SF neutrophils from patients 
with RA. Flow cytometry was performed after incubation of neutrophils with a goat anti-human RANK-L antibody followed by a fluorescein isothiocy-
anate-conjugated anti-goat F(ab')2 antibody. Control isotype antibody was a normal goat immunoglobulin G (IgG). Results shown are representative 
of SF neutrophils from three patients with RA. (c) Samples similar to those in (a) were analyzed by EIAs for OPG. (d) Cell-associated materials of SF 
neutrophils from four patients with RA were solubilized in SDS sample buffer and subjected to SDS-PAGE under reducing conditions (lanes 2 to 5). 
Protein loading values in lanes 2, 3, 4, and 5 were 123, 163, 135, and 125 μg, respectively. COS-7 cells transfected with a human RANK cDNA 
were used as a positive control (lane 1). Western blotting was performed with a goat anti-human RANK antibody, a horseradish peroxidase-conju-
gated anti-goat IgG antibody, and the enhanced chemiluminescence detection system. The position of the molecular weight markers in kilodaltons is 
indicated on the left. OPG, osteoprotegerin; RANK, receptor activator of nuclear factor-kappa-B; RANK-L, ligand of receptor activator of nuclear 
factor-kappa-B.Arthritis Research & Therapy    Vol 9 No 2    Poubelle et al.
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RANK expressed on the surface of neutrophils was functional,
healthy blood neutrophils preincubated 3 days in SF from
patients with RA were stimulated by RANK-L (or TNF-α as a
positive control) and total amounts of I-κB-α protein were eval-
uated by Western blotting. A time-dependent decrease of I-
κB-α protein was demonstrated in the presence of RANK-L or
TNF-α (Figure 5), confirming that the stimulation of cell surface
RANK in neutrophils pretreated with SF from patients with RA
was followed by intracellular signaling through, at least in part,
the NF-κB pathway.
Discussion
The present report is the first to demonstrate that neutrophils
have the capacity to express proteins of the RANK pathway.
We observed the expression of the membrane-associated
form of RANK-L in healthy blood neutrophils. In contrast, SF
neutrophils from patients with RA not only express the mem-
brane-associated form of RANK-L but also express RANK and
secrete OPG. Remarkably, healthy human blood neutrophils
can be induced to express RANK and OPG in response to dif-
ferent stimuli such as IL-4+TNF-α and SF from patients with
RA. The RANK protein expressed on the surface of neutrophils
stimulated by SF from patients with RA is functional since it
can be activated in the presence of RANK-L. Interestingly,
TRAF6 is expressed by both inflammatory and healthy neu-
trophils and its expression is not modulated by any stimulus.
These findings may have important pathophysiological impli-
cations considering that neutrophils are present in large num-
bers at inflammatory sites and are involved in cell-cell
interactions in inflamed tissues.
The fact that SF and blood neutrophils express RANK-L as
membrane materials and that neutrophils incubated in vitro for
up to 4 days generated no soluble RANK-L (Figure 2a) allow
us to consider neutrophils as a new cell type that generates
RANK-L without any release in the extracellular milieu. From
that point of view, neutrophils are different from other cell
types such as osteoblasts, fibroblasts, or T lymphocytes,
which produce RANK-L and release soluble RANK-L after
stimulation [17,24,30,31]. In the context of a chronic inflam-
matory reaction, RANK-L/RANK interactions between T lym-
phocytes and dendritic cells and between T lymphocytes and
osteoclasts explain the role of T cells in disease progression
[17,24,32]. The enhancing effect of SF from patients with RA
on the expression of neutrophil membrane RANK-L (Figure 4a)
should not be neglected in terms of cell-cell interactions. Neu-
trophils have been described at sites of rheumatoid pannus
invasion into cartilage and subchondral bone [5]. Thus, infil-
Figure 3
Effect of cytokines on the expression of RANK-L, OPG, RANK, and TRAF6 mRNAs by normal human blood neutrophils in vitro Effect of cytokines on the expression of RANK-L, OPG, RANK, and TRAF6 mRNAs by normal human blood neutrophils in vitro. Purified neutrophils 
were incubated in control medium (CM) or in survival medium (SM) for 1 to 3 days (D1, D2, D3). After RNA extraction, semi-quantitative reverse tran-
scriptase-polymerase chain reaction analysis was performed. Histograms represent mean ± standard error of the mean of ratios of densitometric val-
ues for RANK-L/β-actin, OPG/β-actin, RANK/β-actin, and TRAF6/β-actin (n = 5 normal donors). Student's paired t test: *p < 0.05 (D3 versus D1, 
D2 versus D1). OPG, osteoprotegerin; RANK, receptor activator of nuclear factor-kappa-B; RANK-L, ligand of receptor activator of nuclear factor-
kappa-B; TRAF6, tumor necrosis factor receptor-associated factor 6.Available online http://arthritis-research.com/content/9/2/R25
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trating neutrophils that, therefore, are numerous and impli-
cated in the local inflammatory process of active immune
diseases could also directly impact on the local immune and
bone remodeling responses through their membrane RANK-L.
The rheumatoid pannus-bone junction at sites of subchondral
bone destruction showed local RANK-L expression that was
more prevalent in active RA [33]. The cellular sources of
RANK-L in these rheumatoid bone destruction sites were not
Figure 4
Induction of the expression of RANK-L, OPG, and RANK by normal human blood neutrophils incubated in the presence of synovial fluid (SF) from  patients with rheumatoid arthritis (RA) or patients with osteoarthritis (OA) Induction of the expression of RANK-L, OPG, and RANK by normal human blood neutrophils incubated in the presence of synovial fluid (SF) from 
patients with rheumatoid arthritis (RA) or patients with osteoarthritis (OA). (a) Surface expression of RANK-L by normal blood neutrophils incubated 
in SF from patients with RA (RA-SF) or OA (OA-SF) for 2 days. Flow cytometry was performed after incubation of neutrophils with a goat anti-human 
RANK-L antibody followed by a fluorescein isothiocyanate (FITC)-conjugated anti-goat F(ab')2 antibody. Control isotype antibody was a normal goat 
immunoglobulin G (IgG). Results shown are representative of three RA-SF and nine OA-SF. (b) Expression of mRNA for OPG and RANK by normal 
blood neutrophils incubated for 2 days in SF from four patients with RA and two patients with OA. Total RNA was isolated from freshly isolated nor-
mal blood neutrophils (D0) and from neutrophils of the same healthy donors after 2 days of incubation in SF (RA-1 to -4, OA-1, -2). RNA was then 
analyzed by reverse transcriptase-polymerase chain reaction. Results shown are representative of two different healthy donors. (c) Surface expres-
sion of RANK by normal blood neutrophils incubated in SF from patients with RA (RA-SF) or OA (OA-SF) for 3 days. Flow cytometry was performed 
after cellular fixation, permeabilization, and staining with a mouse monoclonal anti-human RANK antibody followed by a FITC-conjugated anti-mouse 
F(ab')2 antibody. Control isotype antibody was a non-specific mouse IgG. Results shown are representative of neutrophils from two different healthy 
subjects incubated in three different RA-SF and two OA-SF. OPG, osteoprotegerin; RANK, receptor activator of nuclear factor-kappa-B; RANK-L, 
ligand of receptor activator of nuclear factor-kappa-B.Arthritis Research & Therapy    Vol 9 No 2    Poubelle et al.
Page 10 of 12
(page number not for citation purposes)
all identified with no mention of neutrophils [33]. The present
data on the increased RANK-L expression by RA neutrophils,
together with the presence of neutrophils at the pannus-bone
interface [34], suggest that through cell-cell interactions such
inflammatory neutrophils could activate RANK-expressing
osteoclasts and bone resorption.
The capacity of neutrophils freshly isolated from inflammatory
SFs to express large quantities of OPG (Figures 1a and 2c) in
comparison to the inferior amount of OPG expressed by
healthy blood neutrophils after incubation with certain stimuli
(Figure 3) suggests that the induction of OPG expression by
neutrophils is regulated by multiple factors. In vitro, the maxi-
mal concentration of OPG released by neutrophils in the pres-
ence of IL-4, TNF-α, and GM-CSF was approximately 2 pg/ml.
In contrast, OPG concentrations spontaneously released in
supernatants of SF neutrophils were 200 to 300 pg/ml. It fol-
lows that, if the cytokine combination of IL-4, TNF-α, and GM-
CSF cannot induce neutrophils to express the high concentra-
tions of OPG observed with neutrophils from patients with RA,
other factors are involved in inducing OPG. The effect of IL-4
on neutrophil expression of OPG, however, could be associ-
ated with the anti-apoptotic function of IL-4 through OPG inhi-
bition of TRAIL (tumor necrosis factor-related apoptosis-
inducing ligand) produced by human neutrophils [35,36]. A
synergism between IL-4 and TNF-α has been demonstrated
for the increased production of IL-1 receptor antagonist in
human neutrophils [37]. The exact mechanism (or mecha-
nisms) underlying the synergism that stimulates the neutrophil
expression of OPG remains to be elucidated and could be
independent of or complementary to the NF-κB pathway that
is simultaneously activated by IL-4 and by TNF-α [38,39].
Moreover, IL-4 not only activates human blood neutrophils but
also is a maturation factor for precursors to become neu-
trophils [40] and could drive a subpopulation of neutrophils
and some of their precursors present in blood to express
OPG. The high concentrations of OPG measured in SF from
patients with RA (see Results section) could be related to the
capacity of neutrophils, which are present in large numbers, to
release OPG (Figure 2c). On the other hand, given that RANK-
L was not released by inflammatory neutrophils (Figure 2a), the
low amounts of RANK-L measured in the same SF (see
Results section) could originate only from lining fibroblast-like
synoviocytes [41].
The findings that inflammatory neutrophils spontaneously
express RANK (Figures 1 and 2d) and that healthy blood neu-
trophils express RANK only after stimulation raise the possibil-
ity that neutrophils are involved in bone remodeling. However,
compared with the cytokine combination present in SM, the
SFs from patients with RA are more efficient at activating neu-
trophils to express RANK, indicating that factors other than
GM-CSF+IL-4+TNF-α are implicated in inducing RANK
expression. The production of RANK protein by inflammatory
neutrophils could be related to a pathophysiological role. The
presence of a functional RANK protein at the cell surface of
neutrophils pretreated by SFs from patients with RA, as dem-
onstrated by RANK-L activation of the NF-κB pathway (Figure
5), indicates that such neutrophils contribute to the local tis-
sue response.
Our findings that inflammatory neutrophils from rheumatoid SF
expressed RANK at the mRNA and protein levels further con-
firm the plasticity of neutrophils during inflammation. Similar
results were obtained with neutrophils from SF of patients with
psoriatic arthritis (PE Poubelle, unpublished observations).
Neutrophils can acquire the functional phenotype of active
dendritic cells [10,11]. Mature dendritic cells express RANK
[15,16]. Thus, the demonstration that inflammatory neutrophils
express RANK could be related, in part, to their capacity of
acquiring the functional phenotype of active dendritic cells, as
reported in RA or Wegener granulomatosis [9,10,42,43]. The
exact functions associated with neutrophil expression of
RANK, however, remain to be elucidated. It is of note that neu-
trophil-neutrophil and neutrophil-T lymphocyte interactions
have been described in pathophysiological situations [44].
Moreover, activated neutrophils have several characteristics of
bone-resorbing cells. These characteristics include the capac-
Figure 5
Degradation of inhibitor of kappaB-alpha (I-κB-α) in RANK-L-activated  neutrophils Degradation of inhibitor of kappaB-alpha (I-κB-α) in RANK-L-activated 
neutrophils. I-κB-α was detected in whole-cell lysates by Western blot-
ting as described in Materials and methods. Freshly isolated neu-
trophils (a), or blood neutrophils pretreated for a 3-day incubation 
period in rheumatoid arthritis-synovial fluid (RA-SF) (80%) + control 
medium (20%) (b), were stimulated with 50 ng/ml tumor necrosis fac-
tor-alpha (TNF-α) for 10 minutes or with 100 ng/ml RANK-L for 10 and 
20 minutes. Western blotting was performed with a rabbit anti-human I-
κB-α antibody, a horseradish peroxidase-conjugated anti-rabbit immu-
noglobulin G antibody, and the enhanced chemiluminescence detec-
tion system. Results shown are representative of neutrophils from three 
different healthy subjects incubated in three different RA-SF. RANK-L, 
ligand of receptor activator of nuclear factor-kappa-B.Available online http://arthritis-research.com/content/9/2/R25
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ity to form a ruffled border and the combined expression of
αvβ3 integrin and of certain enzymes (carbonic anhydrase II,
vacuolar ATPase, cathepsin). This lends support to the
hypothesis that neutrophils could be involved in bone
remodeling.
The constant expression of TRAF6 by healthy and inflamma-
tory neutrophils (Figures 1 and 3) suggests that this cytoplas-
mic adapter protein, which is required for immunity and bone
homeostasis, is not a limiting factor in RANK-mediated neu-
trophil effector functions. The present report is the first to
describe TRAF6 expression by neutrophils. These cells have
been found to delay their programmed cell death induced by
TNF-α through NF-κB and TRAF1 induction [45]. Investigation
of neutrophil functions linked to TRAF6 will further our under-
standing of the role of this adapter protein in neutrophil
biology.
Conclusion
Direct evidence is provided for the differential expression of
proteins of the RANK/RANK-L pathway in neutrophils in a non-
inflammatory versus inflammatory context. Moreover, signaling
occurs via RANK, the expression of which is induced in stimu-
lated neutrophils. The results of the present study, therefore,
suggest that neutrophils could play a dual role as immune and
bone-like cells during the inflammatory process. This could
occur via a direct interaction with dendritic cells or osteoclasts
mediated by their membrane RANK-L. In certain inflammatory
conditions, these neutrophils could be directly involved in
acquired immunity or in bone remodeling through their expres-
sion of RANK, depending on the factors present simultane-
ously at the inflammatory site. As has been proposed for
monocyte/macrophage precursor cells that can be driven to
differentiate into dendritic cells or osteoclasts, the acquired
changes of neutrophils reported above could represent an
intermediary phenotype observed during the transdifferentia-
tion of these cells [46].
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